A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Dersimelagon (Primary)
- Indications Erythropoietic protoporphyria
- Focus Adverse reactions; Registrational
- Sponsors Mitsubishi Tanabe Pharma America
- 12 Mar 2024 Planned End Date changed from 1 Dec 2024 to 1 Jun 2025.
- 12 Mar 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2025.
- 25 Jul 2023 Planned End Date changed from 1 Sep 2023 to 1 Dec 2024.